Previous 10 | Next 10 |
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, May 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended Ma...
EDINBURGH, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz, Chief Financial Officer, will host one-on-one m...
Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...
NuCana (NASDAQ: NCNA ): Q4 GAAP EPS of £0.11. Cash and cash equivalents of £77.0M Press Release More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news,
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, March 07, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter an...
EDINBURGH, United Kingdom, March 05, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chi...
EDINBURGH, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc ( NASDAQ:NCNA ) today announced that two abstracts related to NUC-3373 were selected for presentation at the AACR Annual Meeting 2019 to be held March 29 to April 3, 2019, in Atlanta, Georgia. NUC-3373, NuCana...
EDINBURGH, United Kingdom, Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc ( Nasdaq: NCNA ), a clinical-stage biopharmaceutical company (the “Company”) focused on significantly improving treatment outcomes for patients with cancer, announced today that it has withdrawn the proposed ...
Cicero counsels that the study of philosophy, in a lifelong search for basic causes, is an ideal activity, usually serviceable for old people all the way to the grave. - Charlie Munger NuCana (NASDAQ: NCNA ) is a highly promising bioscience company that is focused on the innovation and com...
Thinly traded NuCana plc ( NCNA +2.7% ) is up on average volume following its corporate presentation at Citigroup's Annual Biotech Conference in Boston. The slides are not posted in its website, however. More news on: NuCana plc, Healthcare stocks news, Stocks on the move, Read mor...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...